Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + Paclitaxel in CDK4/6 Activated Tumors
NCT04594005Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Feb 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in solid tumor, sponsored by Yonsei University. Primary endpoints: Overall Response Rate at 8 weeks and Recommended Phase 2 Dose at 28 days. Started Feb 2021; status: completed.
02
Drugs
abemaciclib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04594005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594005.